Clinical trials: Anti-PD-1
Metastatic Cancer, Unresectable Malignant Neoplasm
ImmunoPET With an Anti-CD8 Imaging Agent
This is a single-center, single-arm, investigator sponsored trial designed to evaluate the PK of the anti-CD8 imaging agent in patients prior to and during treatment with checkpoint inhibitors.
- Trial name
- NCT04029181
- Testing
- Anti-CD8 PET imaging agent
- Where
- Netherlands
- Volunteers
- 47 people
- Sponsor
- University Medical Center Groningen
Non-small Cell Lung Cancer Metastatic, Cryotherapy Effect
Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)
Cryo-activation involves the insertion of a cryoprobe in the tumor bed with subsequent cell necrosis and tumor antigens release.
- Trial name
- NCT04793815
- Testing
- Cryo-activation, Pembrolizumab
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Nasopharyngeal Carcinoma
Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients
This is a randomized Phase II trial to study the effectiveness and toxicity of neoadjuvant and adjuvant PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy versus cisplatin concurrent chemoradiotherapy…
- Trial name
- NCT03925090
- Testing
- Cisplatin+Toripalimab
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Sun Yat-sen University
Melanoma
The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma
Currently, the first line treatment options for surgically unresectable metastatic melanoma includes anti-PD1 agents such as nivolumab and pembrolizumab.
- Trial name
- NCT04017897
- Testing
- The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab)
- Where
- South Korea
- Volunteers
- 52 people
- Sponsor
- Yonsei University
Multiple Myeloma
Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
Multiple myeloma (MM) is a common incurable blood cancer causing debilitating symptoms-bone pain, kidney failure, low blood counts and infection.
- Trial name
- NCT02331368
- Testing
- Autologous Stem Cell Transplant, Melphalan, Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- University of Michigan Rogel Cancer Center
Non-small Cell Lung Cancer
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with pumitamig (also known as BNT327 or PM8002) in participants with relapsed, progressive as well…
- Trial name
- NCT07111520
- Testing
- BNT326, Pumitamig
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 880 people
- Sponsor
- BioNTech SE
HCC, Adjuvant Therapy
Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma
Early hepatocellular carcinoma (HCC) recurrence (driven by residual tumors) and late recurrence (driven by de novo tumors) exhibit distinct biological behaviors, suggesting differential therapeutic vulnerabilities.
- Conditions
- HCC, Adjuvant Therapy, Recurrence, Immune Checkpoint Inhibitor
- Trial name
- NCT07379489
- Testing
- PD-1 Inhibitors
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
Recurrent or Metastatic Nasopharyngeal Carcinoma
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
This is a prospective, Bayesian adaptive, phase II clinical trial designed to evaluate the safety and efficacy of four treatment regimens in patients with recurrent (unamenable to local therapy) or metastatic nasopharyngeal…
- Trial name
- NCT07070479
- Testing
- Ivonescimab, Nimotuzumab, Irinotecan liposome
- Where
- 6 sites in China
- Volunteers
- 208 people
- Sponsor
- Ming-Yuan Chen
Non Small Cell Lung Carcinoma, Stage I
Anti PD-1 Neo-adjuvant Treatment for NSCLC
A single arm, phase I, dose escalation trial and expansion cohort, examining the safety and feasibility of neoadjuvant pembrolizumab treatment for early resectable NSCLC patients.
- Conditions
- Non Small Cell Lung Carcinoma, Stage I, Stage II
- Trial name
- MK3475-223 (NCT02938624)
- Testing
- Pembrolizumab 200 mg IV single dose, Pembrolizumab 200 mg IV twice interval 21 days, Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d
- Where
- Israel
- Volunteers
- 28 people
- Sponsor
- Jair Bar, M.D., Ph.D.
Recurrent Cervical Carcinoma, Metastatic Cervical Cancer
SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer
The purpose of this study is to explore the efficacy and safety of SHR-1210 in combination with apatinib in treating patients with metastatic, persistent, or recurrent cervical cancer.
- Trial name
- NCT03816553
- Testing
- SHR-1210, Apatinib
- Where
- 3 sites in China
- Volunteers
- 45 people
- Sponsor
- Sun Yat-sen University
Cervical Cancer
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
The purpose of this study is to assess the efficacy and safety of HLX10(Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection) plus chemotherapy compared to the efficacy and safety of placebo plus chemotherapy in the…
- Trial name
- NCT04806945
- Testing
- HLX10, Paclitaxel, Cisplatin
- Where
- China
- Sponsor
- Shanghai Henlius Biotech
Arthritis, Cancer
Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction
Immune checkpoint inhibitors (ICIs) might have high grade immune-related adverse events (irAEs) from rhumatologic, endocrinologic, cardiac or other system origin.
- Conditions
- Arthritis, Cancer, Cardiac Disease, Endocrine System Diseases
- Trial name
- CHIMeRA (NCT03492242)
- Testing
- Immune checkpoint inhibitor
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival
Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma
This is an open, prospective, single-arm, multi-cohort clinical study to evaluate the efficacy and safety of surufatinib alone or combined with Anti-PD-1 mAb in the treatment of advanced Hepatocellular Carcinoma
- Trial name
- NCT05282433
- Testing
- Surufatinib
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Zhongnan Hospital
Non-Small Cell Lung Cancer (NSCLC)
Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy
Evaluation of FDG PET/CT to image immunotherapy response in adult thoracic cancer. Compare pre- and post-treatment primary tumor uptake for FDG-PET/CT and correlate with clinical markers of response.
- Trial name
- NCT02608528
- Testing
- [18F]fluoroglucose(FDG)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
MSS, pMMR
Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.
The purpose of this study is to evaluate the efficacy and safety of fruquintinib or regorafenib in combination with anti-PD-1 antibody in TKI (fruquintinib or regorafenib)-responded MSS/pMMR metastatic colorectal adenocarcinoma.
- Conditions
- MSS, pMMR, Metastatic Colorectal Adenocarcinoma
- Trial name
- NCT04483219
- Testing
- TKI ± anti-PD-1 antibody
- Where
- China
- Volunteers
- 53 people
- Sponsor
- China Medical University, China
Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma
Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL
This study evaluates the addition of Sintilimab to current 2nd line salvage therapy of Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) for patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).
- Conditions
- Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Trial name
- NCT04659434
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Qian Wenbin
Non Small Cell Lung Cancer
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
A study of tolododekin alfa (also known as ANK-101) administered in combination with an anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody in participants with advanced or metastatic…
- Trial name
- NCT07027514
- Testing
- tolododekin alfa, Cetrelimab
- Where
- 11 sites in United States
- Volunteers
- 60 people
- Sponsor
- Ankyra Therapeutics, Inc
Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage
Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer
This research study is being done to assess the safety and tolerability of study drugs, 177Lu-DOTA0-Tyr3-Octreotate (Lutathera) and nivolumab in subjects with small cell lung cancer or advanced or inoperable neuroendocrine tumor…
- Trial name
- NCT03325816
- Testing
- Nivolumab, 177Lu-DOTA0-Tyr3-Octreotate
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Georgetown University
Carcinoma, Non-Small-Cell Lung
Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy
This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab given in combination with cabozantinib compared with docetaxel monotherapy in patients…
- Trial name
- CONTACT-01 (NCT04471428)
- Testing
- Cabozantinib, Atezolizumab, Docetaxel
- Where
- 92 sites in United States, Australia and 13 more
- Volunteers
- 366 people
- Sponsor
- Hoffmann-La Roche
Neoplasms
Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors
This is a multicenter, open-label, first-in-human Phase 1 study evaluating the anti-lymphocyte activation gene-3 (LAG-3) antibody TSR-033 alone, in combination with the anti-PD-1 antibody dostarlimab, and in combination with…
- Trial name
- CITRINO (NCT03250832)
- Testing
- TSR-033, Dostarlimab, mFOLFOX6
- Where
- 12 sites in United States, France
- Volunteers
- 111 people
- Sponsor
- Tesaro, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.